Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
BLFS Stock Chart & Stats
$25.07
-$0.09(-0.33%)
At close: 4:00 PM EST
$25.07
-$0.09(-0.33%)
Day’s Range― - ―
52-Week Range$19.10 - $29.62
Previous CloseN/A
Volume44.73K
Average Volume (3M)343.72K
Market Cap
$1.21B
Enterprise Value$1.18B
Total Cash (Recent Filing)$78.95M
Total Debt (Recent Filing)$20.68M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding48,148,045
10 Day Avg. Volume307,807
30 Day Avg. Volume343,719
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)3.43
Price to Sales (P/S)14.54
P/FCF Ratio229.80
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue16.01
Enterprise Value/Gross Profit19.99
Enterprise Value/Ebitda-243.21
Forecast
1Y Price Target
$32.29Price Target Upside28.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$96.81M
Bulls Say, Bears Say
Bulls Say
Facility And InnovationThe new facility showcases BioLife's product portfolio and serves as a hub to advance biopreservation and cell processing innovation.
Financial PerformanceFor 3Q25, total revenue was $28.1M, representing 31% YoY growth and beating projections.
Market Position And GrowthBioLife’s biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing over 70% market share.
Bears Say
BioLife Solutions News
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $19.10 and its highest was $29.62 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $1.21B.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is Mar 12, 2026 which is in 82 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.022.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is -0.01.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 48,148,045 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went down -4.034%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.29 (28.80% Upside)
$32.29 (28.80% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 38.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.44%
12-Months-Change
Fundamentals
Return on Equity
-5.20%
Trailing 12-Months
Asset Growth
2.73%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BLFS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioLife Solutions demonstrated solid revenue growth and improved profitability, with strategic moves like the sale of the evo Cold Chain product line strengthening their financial position. However, challenges such as a decline in adjusted gross margin and increased operating expenses were noted. The overall sentiment is positive due to the strong growth metrics and strategic focus on core competencies.View all BLFS earnings summariesBLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
BLFS Stock 12 Month Forecast
Average Price Target
$32.29
▲(28.80% Upside)
Technical Analysis
Azenta
―
Staar Surgical
―
Pulse Biosciences
―
Sanara MedTech
―
Kestra Medical Technologies Ltd.
―
Ownership Overview
Currently, No data available
---